Skip to main content
Oncodesign Precision Medicine S.A logo

Oncodesign Precision Medicine S.A — Investor Relations & Filings

Ticker · ALOPM ISIN · FR001400CM63 LEI · 969500ZDX1IY47LDL876 Euronext Access Plus Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2023-04-13 Earnings Release
Country FR France
Listing Euronext Access Plus ALOPM

About Oncodesign Precision Medicine S.A

https://www.oncodesign.com/

Oncodesign Precision Medicine (OPM) is a biopharmaceutical company specializing in precision medicine. The company's mission is to develop and provide innovative therapeutic and diagnostic solutions to address therapeutic resistance and metastasis in cancer. OPM focuses on creating value through a patient-centric and translational approach, collaborating with clinicians, service providers, and experts. Its core activities are centered on discovering new treatments for resistant and metastatic cancers, aiming to identify the most effective therapeutic pathways for patients.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled with a headline announcing 'résultats annuels 2022' (2022 annual results) and contains detailed financial tables comparing 2022 audited figures against 2021 proforma figures, including Revenue, Operating Income, Net Result, and detailed expense breakdowns. This content strongly indicates a comprehensive annual financial disclosure. However, the document is structured as a 'COMMUNIQUE DE PRESSE' (Press Release) and explicitly mentions: 'Le Rapport Financier 2022 sera disponible sur le site internet de la société , le lundi 24 avril 2022.' (The 2022 Financial Report will be available on the company's website on Monday, April 24, 2022). Furthermore, it announces the upcoming 'Assemblée Générale Ordinaire le 30 mai 2023' (Ordinary General Meeting on May 30, 2023). Since this document is a press release summarizing the annual results rather than the full, formal 'Rapport Financier' (which would typically be the 10-K equivalent or a full Annual Report), and given the presence of key financial highlights and management commentary, it fits best as an Earnings Release (ER) or potentially an Interim/Quarterly Report (IR) if it were quarterly. Since it explicitly covers the full year ('résultats annuels 2022'), it is the initial announcement of the annual performance. If the document were the full audited report, it would be classified as 10-K. Since it is the press release announcing these results, 'ER' (Earnings Release) is the most appropriate classification, even though it covers annual results, as it serves the function of the initial results announcement. If the document had only announced the *availability* of the report without providing the detailed financial summary, it would be RPA. Since it provides the summary, ER is better. FY 2022
2023-04-13 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is a press release ("COMMUNIQUÉ DE PRESSE") from Oncodesign Precision Medicine announcing the publication date for its annual results ("résultats annuels 2022") on April 13, 2023. It explicitly states that the financial report will also be available on that date. Since the document itself is an announcement about *when* a report will be released, and not the report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (3061 chars) is short, supporting the 'MENU VS MEAL' rule application.
2023-03-13 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is clearly labeled as a "PRESS RELEASE" announcing a significant corporate and clinical development: the initiation of Phase I of their drug candidate ODS-101 in healthy volunteers. This type of announcement, detailing clinical trial progress, strategic milestones, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate update. Since it is a press release announcing key operational and clinical progress rather than a comprehensive financial report (10-K, IR) or a transcript (CT), the most fitting category is Earnings Release (ER), which often encompasses major operational news alongside financial highlights, or potentially Regulatory Filing (RNS) if it were a mandatory filing. Given the structure and content focusing on a major milestone ('First-in-Man study'), ER is the best fit among the provided options for a major operational announcement. However, upon reviewing the definitions, ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is purely clinical/operational news, not primarily financial results. It is a press release announcing a clinical trial initiation. This type of announcement often falls under general Regulatory Filings (RNS) if it doesn't fit a more specific category like Capital/Financing (CAP) or M&A (TAR). Since it is a significant, non-financial operational update, and not a formal report itself, RNS serves as the best general regulatory announcement category when specific clinical/operational codes are absent. Given the options, RNS is the most appropriate fallback for a significant, non-financial press release detailing clinical progress.
2023-02-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant operational milestone: the entry into Phase I clinical trials for the drug candidate ODS-101. It includes quotes from the CEO and CSO, details about the drug, the market context (MICI), and contact information for investors and media. This format is characteristic of an initial announcement of key business or clinical progress, rather than a comprehensive periodic financial report (like 10-K or IR) or a formal regulatory filing for shareholder votes (like DEF 14A). Since it is an announcement of results/progress, it fits best under the 'Earnings Release' (ER) category if it were financial results, but since it is a clinical/operational update, and given the available options, it most closely resembles a general corporate announcement. However, in the context of financial reporting databases, press releases announcing major operational milestones (like clinical trial initiation) are often categorized as 'Regulatory Filings' (RNS) if they don't fit a more specific operational category like 'Capital/Financing Update' or 'M&A Activity'. Given the options, and recognizing this is a press release detailing a major development, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate fallback, although 'ER' (Earnings Release) is sometimes used broadly for major company news releases. Since this is not financial earnings, RNS is the better fit as a general, material corporate announcement.
2023-02-09 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release titled "Publication of the 2023 financial calendar". It explicitly lists future dates for key events like the '2022 Annual Results', 'Annual General Meeting', and '2023 First Half Results'. Since the document's primary function is to announce *when* future reports and meetings will occur, rather than containing the full content of those reports (like a 10-K or IR), it fits the definition of a Report Publication Announcement (RPA). The document length (2939 chars) is short, supporting the idea that it is an announcement rather than the full report itself.
2023-02-07 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and its main purpose is to publish the indicative financial calendar for the year 2023, listing dates for the 2022 annual results, the General Meeting, and H1 2023 results. Since the document's sole function is to announce the schedule for future corporate events and reports, it fits the definition of a Report Publication Announcement (RPA). It is not the report itself (like 10-K or IR), nor is it a transcript (CT) or an earnings release (ER) containing actual results. The short length (3238 chars) and the nature of announcing future publications strongly support the RPA classification.
2023-02-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.